Inovio Pharmaceuticals Inc
INO
Company Profile
Business description
Inovio Pharmaceuticals Inc is a United States-based biotechnology company. The company is focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Contact
660 West Germantown Pike
Suite 110
Plymouth MeetingPA19462
USAT: +1 267 440-4200
E: ben.matone@inovio.com
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
134
Stocks News & Analysis
stocks
Looking under the hood at Robinhood
We review some of the platform's most popular stocks on 11 different measures of equity-related risk.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,524.30 | 323.30 | -4.12% |
| CAC 40 | 6,927.12 | 347.83 | -4.78% |
| DAX 40 | 19,789.62 | 852.10 | -4.13% |
| Dow JONES (US) | 37,861.32 | 2,684.61 | -6.62% |
| FTSE 100 | 7,702.08 | 352.90 | -4.38% |
| HKSE | 19,828.30 | 3,021.51 | -13.22% |
| NASDAQ | 15,520.92 | 1,029.69 | -6.22% |
| Nikkei 225 | 31,136.58 | 2,644.00 | -7.83% |
| NZX 50 Index | 11,775.88 | 449.40 | -3.68% |
| S&P 500 | 5,044.14 | 29.94 | -0.59% |
| S&P/ASX 200 | 7,343.30 | 324.50 | -4.23% |
| SSE Composite Index | 3,096.58 | 245.43 | -7.34% |